[1]金吉明,吴艳杰,闫世林,等.慢性阻塞性肺疾病急性加重期患者血清甘油磷脂代谢物LPC18∶3，LPE 16∶1 水平变化与临床预后相关性研究[J].现代检验医学杂志,2024,39(04):93-99.[doi:10.3969/j.issn.1671-7414.2024.04.017]
　JIN Jiming,WU Yanjie,YAN Shilin,et al.Study on the Correlation between Changes in Serum Glycerophospholipid Metabolites LPC18∶3 and LPE 16∶1 Levels and Their Clinical Prognosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2024,39(04):93-99.[doi:10.3969/j.issn.1671-7414.2024.04.017]
点击复制

慢性阻塞性肺疾病急性加重期患者血清甘油磷脂代谢物LPC18∶3，LPE 16∶1 水平变化与临床预后相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
93-99
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Study on the Correlation between Changes in Serum Glycerophospholipid Metabolites LPC18∶3 and LPE 16∶1 Levels and Their Clinical Prognosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1671-7414（2024）04-093-07
作者:
金吉明; 吴艳杰; 闫世林; 李占增; 柳 洋
（唐山市人民医院急诊科，河北唐山 063000）
Author(s):
JIN Jiming;  WU Yanjie;  YAN Shilin;  LI Zhanzeng;  LIU Yang
（Department of Emergency , Tangshan People’s Hospital, Hebei Tangshan 063000, China）
关键词:
慢性阻塞性肺疾病急性加重期; 溶血磷脂酰胆碱18∶3; 溶血磷脂酰乙醇胺16∶1
分类号:
R563；R446.11
DOI:
10.3969/j.issn.1671-7414.2024.04.017
文献标志码:
A
摘要:
目的 探索慢性阻塞性肺疾病急性加重期（acute exacerbation of chronic obstructive pulmonary disease，AECOPD）患者血清甘油磷脂代谢物溶血磷脂酰胆碱（lysophosphatidylctholine，LPC）18∶3，溶血磷脂酰乙醇胺（lysophosphatidylethanolamine,LPE）16 ∶1 水平及两者对临床预后的相关性研究。方法 选取2019 年1 月~2022 年1 月唐山市人民医院诊治的112 例AECOPD 患者为AECOPD 组，根据随访3 个月预后分为生存组（n=90）和死亡组（n=22）。以同期60 例COPD 稳定期患者为稳定期组，60 例健康人群为对照组。应用高效液相色谱- 串联质谱法(HPLC-MS/MS) 检测各组血清LPC18∶3 和LPE16∶1 水平。相关性采用Pearson 相关性分析。Logistic 回归分析AECOPD 患者预后影响因素。受试者工作特征（ROC）曲线分析LPC18∶3，LPE16∶1 的预后评估价值。K-M 曲线比较不同血清LPC18∶3 和LPE16∶1 表达组AECOPD 患者预后差异。结果 AECOPD 组血清LPC18:3（21.67±4.35μmol/L)、LPE16∶1（16.20±5.17μmol/L)、峰值呼气流速占预计值的百分比（PEF%pred）、第1 秒用力呼气容积占预计值百分比（FEV1%pred），1 秒钟用力呼气容积占用力肺活量百分比（FEV1/FVC%）低于稳定期组（43.24±6.17μmol/L，32.19±5.98μmol/L） 和对照组（68.14±8.78μmol/L,44.82±7.44μmol/L）， 差异具有统计学意义（F/χ2=461.240~1 102.534，均P<0.05）。AECOPD 组血清LPC18∶3，LPE16∶1 水平与肺功能指标PEF%pred，F%pred，FEV1/FVC%呈显著正相关（r=0.603 ～ 0.756，均P<0.05）。死亡组AECOPD 患者COPD 病程、降钙素原高于生存组（t=3.961，2.509)，PEF%pred，FEV1%pred，FEV1/FVC%，血清LPC18:3（17.20±4.11μmol/L）和LPE16:1（10.15±3.03μmol/L）低于生存组（22.76±4.35μmol/L，17.68±5.22μmol/L），差异具有统计学意义（t=4.141 ～ 6.490，均P ＜ 0.05）。血清LPC18:3（OR=0.691，95%CI:0.519~0.920)，LPE16:1（OR=0.586，95%CI:0.382~0.901）是影响AECOPD 患者预后独立保护因素；COPD 病程（OR=1.510，95%CI:1.203~1.895）、降钙素原（OR=1.759，95%CI:1.159~2.671）是危险因素。血清LPC18∶3，LPE 16∶1 二者联合对AECOPD 患者预后评估的曲线下面积（95%CI）为0.866（0.822~0.907），优于血清LPC18∶3，LPE16∶1 单独预测的0.794（0.748~0.830），0.786（0.739~0.836），差异具有统计学意义（Z=3.957，4.195，P=0.002，＜ 0.001）。血清LPC18∶3，LPE16∶1 低表达组AECOPD 患者的死亡风险高于血清LPC18∶3，LPE16∶1 高表达组，差异具有统计学意义（Log-Rankχ2=4.475，5.763，P=0.034，0.016）。结论 AECOPD 患者血清甘油磷脂代谢物LPC18:3，LPE16:1 水平显著降低，与肺功能状况有关，两者联合能够有效评估AECOPD 患者预后。
Abstract:
Objective To explore the expression levels of serum glycerophospholipid metabolites lysophosphatidylcholine (LPC) 18 ∶3 and lysophosphatidylethanolamine (LPE) 16 ∶1 in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and their correlation with clinical prognosis. Methods A total of 112 AECOPD patients diagnosed and treated in Tangshan People’s Hospital from January 2019 to January 2022 were selected as the AECOPD group. According to the 3-month follow-up prognosis of the AECOPD group patients, they were divided into survival group (n=90) and death group (n=22). During the same period, 60 stable COPD patients were selected as the stable period group, while 60 healthy individuals in the same period were selected as the control group. High performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) was used to detect serum LPC18∶3 and LPE16∶1 levels in each group. Pearson method was used to analyze their correlation. Logistic regression analysis was used to analyze factors affecting the prognosis of AECOPD patients. Receiver operating characteristic curve was drawn to evaluate the prognostic value of LPC18∶3 and LPE16∶1 in AECOPD patients. The prognosis of AECOPD patients with different serum LPC18∶3 and LPE16∶1 expression groups was compared by K-M curve. Results Serum LPC18∶3 (21.67±4.35μmol/L ), LPE16∶1 (16.20±5.17μmol/L ), PEF% pred, FEV1% pred, and FEV1/ FVC% in AECOPD group were lower than those of stable phase group (43.24±6.17μmol/L, 32.19±5.98μmol/L)and the control group (68.14±8.78μmol/L, 44.82±7.44μmol/L), with significant differences (F=461.240~1 102.534, all P<0.05). The serum LPC18∶3 and LPE16:1 levels in the AECOPD group were positively correlated with lung function indicators such as PEF% pred, FEV1% pred, and FEV1/FVC% (r=0.603~0.756, allP<0.05). The course of COPD and PCT of AECOPD patients in the death group were higher than those in the survival group(t=3.961,2.509),while the PEF% pred, FEV1% pred, FEV1/FVC%, serum LPC18∶3 (17.20±4.11μmol/L ), and LPE16∶1 (10.15±3.03μmol/L) in the death group were lower than those in the survival group(22.76±4.35μmol/L, 17.68±5.22μmol/L), with significant differences (t=4.141 ～ 6.490, all P<0.05). Serum LPC18∶3 (OR=0.691, 95%CI:0.519~0.920) and LPE16∶1 (OR=0.586, 95%CI:0.382~0.901) were independent protective factors, while the course of COPD (OR=1.510, 95%CI:1.203~1.895) and procalcitonin (OR=1.759, 95%CI:1.159~2.671) were risk factors affecting the prognosis of AECOPD patients. The area under the curve (95%CI) of combined serum LPC 18 ∶3 and LPE16∶1 for prognosis evaluation of AECOPD patients was better than that of serum LPC18 ∶3 and LPE16∶1 predicted separately [0.866 (0.822~0.907) vs 0.794 (0.748~0.830), 0.786 (0.739~0.836)] (Z=3.957, 4.195, P=0.002, <0.001). The mortality risk of AECOPD patients in the low expression group of LPC 18:3 and LPE16∶1 was higher than that in the high expression group of LPC18 ∶3 and LPE16∶1 (log rankχ2=4.475, 5.763, P=0.034, 0.016). Conclusion The serum levels of glycerophospholipid metabolites LPC18∶3 and LPE16∶1 in AECOPD patients were decreased, which were related to lung function status. The combination of the two may effectively evaluate the prognosis of AECOPD patients.

参考文献/References:

[1] CHRISTENSON S A, SMITH B M, BAFADHEL M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342): 2227-2242.
[2] ADIBI A, SIN D D, SAFARI A, et al. The acute COPD exacerbation prediction tool (ACCEPT): a modelling study[J]. The Lancet Respiratory Medicine, 2020, 8(10): 1013-1021.
[3] 方德刚, 肖清华, 杨柳, 等. 2 型糖尿病并发非酒精 性脂肪性肝炎患者血清脂质组学分析及诊断价值研 究[J]. 现代检验医学杂志, 2023, 38(3): 159-164. FANG Degang, XIAO Qinghua, YANG Liu, et al. Serum lipomics analysis and diagnostic value of type 2 diabetes patients with nonalcoholic steatohepatitis[J]. Journal of Modern Laboratory Medicine, 2023, 38(3): 159-164.
[4] GAI Xiaoyan, ZHANG Lijiao, CHANG Chun, et al. Metabolomic analysis of serum glycerophospholipid levels in eosinophilic and neutrophilic asthma[J]. Biomedical and Environmental Sciences, 2019, 32(2): 96-106.
[5] CHEN Haipin, LI Zhouyang, DONG Lingling, et al. Lipid metabolism in chronic obstructive pulmonary disease[J]. International Journal of Chronic Obstructive Pulmonary Disease, 2019, 14: 1009-1018.
[6] GAI Xiaoyan, GUO Chenglin, ZHANG Linlin, et al. Serum glycerophospholipid profile in acute exacerbation of chronic obstructive pulmonary disease[J]. Frontiers in Physiology, 2021, 12: 646010.
[7] WANG Yating, CHANG Chun, TIAN Sifan, et al. Differences in the lipid metabolism profile and clinical characteristics between eosinophilic and noneosinophilic acute exacerbation of chronic obstructive pulmonary disease[J].Frontiers in Molecular Biosciences, 2023, 10: 1204985.
[8] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作 委员会. 慢性阻塞性肺疾病诊治指南（2021 年修订 版）[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205. Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society, Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2021, 44(3): 170-205.
[9] FAN Xiaoye, DONG Tingting, YAN Kun, et al. PM2.5 increases susceptibility to acute exacerbation of COPD via NOX4/Nrf2 redox imbalance-mediated mitophagy[J]. Redox Biology, 2023, 59: 102587.
[10 MART?NEZ-GESTOSO S, GARC?A-SANZ M T, CALVO-?LVAREZ U, et al. Variability of blood eosinophil count and prognosis of COPD exacerbations[J]. Annals of Medicine, 2021, 53(1): 1152-1158.
[11] DENG Mingming, YIN Yan, ZHANG Qin, et al. Identification of Inflammation-Related biomarker Lp-PLA2 for patients with COPD by comprehensive analysis[J]. Frontiers in Immunology, 2021, 12: 670971.
[12] ZHANG Wen, DUN Su, PING Yin, et al. Differentially expressed long noncoding RNAs and mRNAs in PC12 cells under lysophosphatidylcholine stimulation[J]. Scientific Reports, 2022, 12(1): 19333.
[13] BEAULIEU D, ATTWE A, BREAU M, et al. Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease[J]. European Respiratory Journal, 2021, 58(2): 2000752.
[14] WANG Bo, TONTONOZ P. Phospholipid remodeling in physiology and disease[J]. Annual review of Physiology, 2019, 81: 165-188.
[15] TLATELPA-ROMERO B, C?ZARES-ORDO?EZ V, OYARZ?BAL L F, et al. The role of pulmonary surfactant phospholipids in fibrotic lung diseases[J]. International Journal of Molecular Sciences, 2022, 24(1): 326.
[16] CHRISTMANN U, PAGE A E, HOROHOV D W, et al. Lipidomic analysis of surfactant and plasma from horses with asthma and age-matched healthy horses[J]. American Journal of Veterinary Research, 2022, 83(9): ajvr.21.11.0179.
[17] CRUICKSHANK-QUINN C I, JACOBSON S, HUGHES G, et al. Metabolomics and transcriptomics pathway approach reveals outcome-specific perturbations in COPD[J]. Scientific Reports, 2018, 8(1): 17132.
[18] HALPER-STROMBERG E, GILLENWATER L, CRUICKSHANK-QUINN C, et al. Bronchoalveolar lavage fluid from COPD patients reveals more compounds associated with disease than matched plasma[J]. Metabolites, 2019, 9(8): 157.
[19] ETO M, SHINDOU H, YAMAMOTO S, et al. Lysophosphatidylethanolamine acyltransferase 2 (LPEAT2) incorporates DHA into phospholipids and has possible functions for fatty acid-induced cell death[J]. Biochemical and Biophysical Research Communications, 2020, 526(1): 246-252.

相似文献/References:

[1]王媛a,田应选b,杨春芳a.血清炎性标志物对老年慢性阻塞性肺疾病的临床诊断价值研究[J].现代检验医学杂志,2015,30(05):121.[doi:10.3969/j.issn.1671-7414.2015.05.037]
　WANG Yuana,TIAN Ying-xuanb,YANG Chun-fanga.Study on the Value of Three Serum Biomarkers for Diagnosis Elderly Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2015,30(04):121.[doi:10.3969/j.issn.1671-7414.2015.05.037]
[2]崔雨佳,刘　忠.外周血嗜酸性粒细胞水平与慢性阻塞性肺疾病急性加重期患者临床预后的相关性分析[J].现代检验医学杂志,2020,35(03):129.[doi:10.3969/j.issn.1671-7414.2020.03.035]
　CUI Yu-jia,LIU Zhong.Relationship between Peripheral Blood Eosinophil Level and the Prognosis of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Modern Laboratory Medicine,2020,35(04):129.[doi:10.3969/j.issn.1671-7414.2020.03.035]
[3]黄明民,李 丹,李 凰,等.AECOPD 患者血清FOXM1 和CCR5 水平与肺功能及预后的预测价值研究[J].现代检验医学杂志,2024,39(03):176.[doi:10.3969/j.issn.1671-7414.2024.03.030]
　HUANG Mingmin,LI Dan,LI Huang,et al.Predictive Value of Serum FOXM1 and CCR5 Levels in AECOPD Patients with Lung Function and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(04):176.[doi:10.3969/j.issn.1671-7414.2024.03.030]

备注/Memo

备注/Memo:
基金项目：河北省医学科学研究课题（20191726）。
作者简介：金吉明（1964-），男，本科，副主任医师，研究方向：急诊医学，E-mail：jinjiming7797@126.com。
更新日期/Last Update: 2024-07-15